In today’s fast-evolving life sciences landscape, transactions such as acquisitions and in-licensing are strategic levers for growth. Yet, despite their frequency, many fail to deliver their intended value. Why? One often underestimated reason: insufficient integration of Quality early in the transaction lifecycle.
At Qintegro Consulting GmbH, we believe that quality is not just a compliance obligation — it’s a strategic enabler. In acquisitions and in-licensing deals, overlooking quality due diligence and integration planning can expose organizations to operational delays, compliance risks, and erosion of product or asset value.
Whether acquiring a company or licensing a promising asset, success hinges on understanding the maturity and robustness of its quality systems — from development to commercial operations. This includes verifying regulatory inspection readiness, data integrity, supply chain reliability, and the ability to seamlessly integrate with the buyer’s or licensor’s existing processes.
Our experience shows that a structured, quality-focused approach in the early phases of M&A or licensing — starting from target screening through to integration — is key to preserving asset value, ensuring continuity, and accelerating return on investment.
At Qintegro, we help you ask the right questions early — so you avoid bigger problems later.